AlphaYou
Overview
No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.
Key stats
Aug 20- 52-wk high
- $35.43
- 52-wk low
- $23.62
- Prev close
- $29.43
- Mkt cap
- $21.27B
- P/E
- 26.0x
- Fwd P/E
- 20.2x
Smart money
Earnings
Earnings came in 45.9% above what analysts expected.
Financials
What it sold, what it cost, what was left.
Sep 2025Dec 2025Mar 2026Jun 2026
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.02B | $1.05B | $899.3M | $1.16B |
| Cost of what it sold | $58.0M | $80.8M | $65.2M | $84.0M |
| Gross profit | $964.0M | $974.1M | $834.1M | $1.07B |
| What it spent | ||||
| Research and development | $357.0M | $524.4M | $441.6M | $459.0M |
| Sales and admin | $148.0M | $208.0M | $166.0M | $205.0M |
| Total operating expenses | $505.0M | $731.8M | $608.2M | $664.0M |
| What was left | ||||
| Operating profit | $459.0M | $242.3M | $225.8M | $407.0M |
| Interest on debt | $3.0M | $43.9M | $112.4M | $110.0M |
| Profit before tax | $482.0M | $54.8M | $74.3M | $295.0M |
| Tax | $81.0M | $23.9M | $21.1M | -$8.0M |
| Net profit | $401.0M | $30.9M | $53.2M | $303.0M |
| EBITDA | $503.0M | $98.7M | $186.7M | $431.0M |
Technicals
Price structure
No data yet
Technicals sync when verified market data is available. No sample data is shown.
News
What the news says
25 articles · 7 days
Coverage is bullish
Tone of tracked coverage
Is Genmab (CPSE:GMAB) Fairly Valued On Raised Revenue Guidance And Q2 Results?
Leans bullishAug 18Genmab A/S (GMAB): Orbis and Allan Gray report 5.3% beneficial ownership stake
NeutralAug 14Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Definitive Healthcare Corp (DH) and Atai Beckley N.V. (ATAI)
BullishAug 13
